548 related articles for article (PubMed ID: 32768563)
1. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
2. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.
Carrie C; Grill J; Figarella-Branger D; Bernier V; Padovani L; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Baron MH; Clavere P; Chapet S; Maingon P; Alapetite C; Claude L; Laprie A; Dussart S
J Clin Oncol; 2009 Apr; 27(11):1879-83. PubMed ID: 19273707
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy.
Gupta T; Jalali R; Goswami S; Nair V; Moiyadi A; Epari S; Sarin R
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1534-40. PubMed ID: 22342098
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy.
Câmara-Costa H; Resch A; Kieffer V; Lalande C; Poggi G; Kennedy C; Bull K; Calaminus G; Grill J; Doz F; Rutkowski S; Massimino M; Kortmann RD; Lannering B; Dellatolas G; Chevignard M;
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):978-985. PubMed ID: 26194675
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
[TBL] [Abstract][Full Text] [Related]
7. Intellectual Outcome in Molecular Subgroups of Medulloblastoma.
Moxon-Emre I; Taylor MD; Bouffet E; Hardy K; Campen CJ; Malkin D; Hawkins C; Laperriere N; Ramaswamy V; Bartels U; Scantlebury N; Janzen L; Law N; Walsh KS; Mabbott DJ
J Clin Oncol; 2016 Dec; 34(34):4161-4170. PubMed ID: 27507873
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
9. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
10. Critical combinations of radiation dose and volume predict intelligence quotient and academic achievement scores after craniospinal irradiation in children with medulloblastoma.
Merchant TE; Schreiber JE; Wu S; Lukose R; Xiong X; Gajjar A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):554-61. PubMed ID: 25160611
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for children with medulloblastoma.
Michiels EM; Schouten-Van Meeteren AY; Doz F; Janssens GO; van Dalen EC
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD006678. PubMed ID: 25879092
[TBL] [Abstract][Full Text] [Related]
13. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.
Carrie C; Muracciole X; Gomez F; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Soum F; Baron MH; Clavere P; Chapet S; Gaci Z; Kolodie H; Maingon P; Vie B; Bernier V; Alapetite C; Hoffstetter S; Grill J; Lafay F;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):711-6. PubMed ID: 15927408
[TBL] [Abstract][Full Text] [Related]
14. Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.
Lee JW; Lim DH; Sung KW; Cho HW; Ju HY; Hyun JK; Yoo KH; Koo HH; Suh YL; Joung YS; Shin HJ
Cancer Med; 2020 Aug; 9(16):5807-5818. PubMed ID: 32608158
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
16. Subgroup and subtype-specific outcomes in adult medulloblastoma.
Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
[TBL] [Abstract][Full Text] [Related]
17. Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma.
Tian S; Sudmeier LJ; Zhang C; Madden NA; Buchwald ZS; Shu HG; Curran WJ; Eaton BR; Esiashvili N
Pediatr Blood Cancer; 2020 Jan; 67(1):e28027. PubMed ID: 31571408
[TBL] [Abstract][Full Text] [Related]
18. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma.
Moxon-Emre I; Bouffet E; Taylor MD; Laperriere N; Scantlebury N; Law N; Spiegler BJ; Malkin D; Janzen L; Mabbott D
J Clin Oncol; 2014 Jun; 32(17):1760-8. PubMed ID: 24516024
[TBL] [Abstract][Full Text] [Related]
19. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
Kortmann RD; Kühl J; Timmermann B; Mittler U; Urban C; Budach V; Richter E; Willich N; Flentje M; Berthold F; Slavc I; Wolff J; Meisner C; Wiestler O; Sörensen N; Warmuth-Metz M; Bamberg M
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):269-79. PubMed ID: 10661332
[TBL] [Abstract][Full Text] [Related]
20. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
Massimino M; Vennarini S; Buttarelli FR; Antonelli M; Colombo F; Minasi S; Pecori E; Ferroli P; Giussani C; Schiariti M; Schiavello E; Biassoni V; Erbetta A; Chiapparini L; Nigro O; Boschetti L; Gianno F; Miele E; Modena P; De Cecco L; Pollo B; Barretta F
J Neurooncol; 2023 Jul; 163(3):577-586. PubMed ID: 37326761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
